Skip to main content

Biomarkers in Pediatric Therapeutics Scientific Interest Group

The Trans-NIH Biomarkers in Pediatric Therapeutics Special Interest Group was developed in an effort to pursue opportunities for strengthening cross-disciplinary pediatric biomarkers research at NIH while innovating beyond existing investments. Its goals are to: 

• Provide leadership, vision, and support to promote a strong body of NIH-funded pediatric biomarkers research
• Share knowledge on pediatric biomarkers research across institutions, disciplines, and NIH Institutes and Centers (ICs)
• Collect, evaluate, and disseminate scientific information and funding opportunities for biomarkers research in pediatric therapeutics at the NIH
• Promote interactions and collaborations between intramural and extramural scientists, and between academic and industry researchers
• Promote interactions and collaboration between pediatric and adult subspecialists involved in biomarkers research

The diversity of biomarkers coupled with different types of investigators from various disciplines dictates the need to organize the SIG along functional lines that allows flexibility and satisfaction of general and specific goals.

The clinical areas of interest are: asthma, diabetes, infectious disseases, cardiact diseases, neonatology, rare diseases, neurology, pediatric intensive care, mental disorders, oncology, and autism spectrum disorders.

The translational/regulatory areas of interest are: 

  • Translational/basic (links with developmental biology and method development)
  • Biomedical imaging and new technologies
  • Pediatric pharmacology (pharmacogenetics, pharmacogenomics, and pharmacometrics)

The NIH SIG members include Program Officers (POs), Program Directors (PDs), and intramural investigators from different ICs. Academic members may be recruited by POs whose portfolio contains research on pediatric biomarkers, as well as those involved in pediatric drug networks. The POs of pediatric drug networks may identify biomarker researchers that can make different contributions to the different core groups or to the overall SIG objectives. Members of working groups established under the BPCA program will be invited to participate in appropriate subgroups. Involvement of investigators from industry will be secured via contacts already established.

SIG activities will be coordinated by an interdisciplinary Steering Committee, consisting of one leader from each core group. The Steering Committee will oversee the setting up of meetings and educational offerings and facilitate development of strategies to propose studies for funding by the NIH. The Steering Committee will organize meetings on the use of biomarkers in pediatric therapeutics with participation of NIH scientists, PDs, academic and industry researchers who are members of the core groups, and invited guests. These meetings are designed to establish and implement a roadmap for research in pediatric therapeutics.

Didactic and information exchange meetings will involve the SIG as a whole or the individual core groups. For the benefit of a widely dispersed membership, a combination of face-to-face meetings and webinars will be held.

Since January 2016, didactic lectures on biomarkers in pediatric therapeutics have been presented as part of the Sumner J. Yaffe Memorial Lecture Series in Pediatric Clinical Pharmacology. Lectures deal with issues related to the application of new technologies, discovery and adaptation of biomarkers in pediatric drug development, and application to patient management or as part of clinical drug trials. Lectures have been offered both in-person and via Webinar and feature guest reactors to provide additional perspective, comments, and expert feedback. The current schedule can be found here.

To join the group, contact George Giacoia at



The page was last updated on Tuesday, January 16, 2018 - 6:00pm